It has been shown that the efficacy of first-line GBM treatment, temozolomide (TMZ), is largely dependent on p53 status in the tumor [10], where mutant p53 status confers enhanced proliferative abilities in the tumor and resistance to TMZ [11]. The gene discussed is TP53; the disease is neoplasm.